We herein report a case of a 37-year-old Brazilian man born in Minas Gerais, an endemic area of leishmaniasis in Brazil, who was receiving treatment with infliximab from 2005 to 2015 and since 2015 has been in use of adalimumab 40 mg every 2 weeks for ankylosing spondylitis. He presented to the otolaryngologist outpatient clinic of the University of São Paulo Medical School Hospital complaining of rhinorrhea and nasal obstruction for the last 3 months. Nasopharyngolaryngoscopy revealed a nasal granulomatous lesion with crust formation. The lesion was biopsied and initial hypotheses were leishmaniasis, lymphoma, syphilis, and Wegener granulomatosis. Antineutrophil cytoplasmic antibodies (ANCA) were negative. Serological assays for leishmaniasis were positive: ELISA with titers above 1:1280 and indirect immunofluorescence with a titer of 1:80. Hematoxylin and eosin staining showed a chronic lymphoplasmocytic infiltrate with ulcerated areas in the nasal mucosa (Fig 1). Amastigote forms were not visualized by optic microscopy. Polymerase chain reaction (PCR) was positive for Leishmania in the biopsy tissue [1]. Surprisingly, immunohistochemistry of the biopsy revealed CD3-positive, CD20-negative, CD56-negative, CD30-negative, Cyclin D1-negative, Ki-67-positive (high levels), CD4-positive (focal), CD8-positive (focal), CD7-positive, TIA-1-positive, and Granzyme B-positive cells, suggesting natural killer (NK)/T-cell lymphoma (Fig 2). The patient underwent a positron emission tomography (PET)/computed tomography (CT) scan, which was negative. CT scans of the sinus, chest, and abdomen were normal. In spite of the immunohistochemistry results, he was treated with a liposomal amphotericin B cumulative dose of 35 mg/kg [2], with complete remission of the lesions after 3 months. Seven months after treatment, the patient returned with complaints of rhinorrhea, nose bleeding, and congestion. Coincidentally, he had been reinitiated on adalimumab 3 months earlier, prescribed by a rheumatologist. A new nasopharyngolaryngoscopy examination showed an ulcer with infiltrated borders in the left nasal septum. We decided on retreatment with 35 mg/kg of amphotericin B lipid complex. Four months after retreatment, the patient was asymptomatic and the ulcer had healed. We decided to maintain secondary prophylaxis with 3 mg/kg of liposomal amphotericin B every 3 weeks for as long as the patient was on maintenance treatment with adalimumab.